On December 20, 2019 MonTa Biosciences reported completion of a Series A investment from existing investor Consolidated Biosciences Aps of 40 mDKK to secure completion of a phase I study in cancer patients (Press release, MonTa Biosciences, DEC 20, 2019, View Source [SID1234552933]). The study will test the lead asset of MonTa Biosciences MBS8, which is a promising immunotherapy to boost the immune system of cancer patients using a unique technology to activate the patients immune system. MBS8 is a nanoparticle consisting of a small molecule compound of the TLR7 class formulated in micelles, and is administered by the intravenous route to activate immune cells of the patient. The phase I trial will enroll patients with solid tumors and be conducted in Denmark and Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!